Moleculin Participates in Virtual Investor “What This Means” Segment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2025
0mins
Source: Globenewswire
Moleculin Biotech Update: Moleculin Biotech, Inc. announced positive FDA feedback on its Pediatric Study Plan for Annamycin, a drug targeting relapsed/refractory acute myeloid leukemia in children, during a Virtual Investor segment featuring CEO Walter Klemp.
Clinical Development and Future Plans: The company is advancing its Phase 3 clinical trial (MIRACLE) for Annamycin, designed to be non-cardiotoxic, while also developing other therapeutic candidates like WP1066 for various cancers and viral infections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
